Ascendis Pharma A/S (Ascendis Pharma A/S) Float Percentage Of Total Shares Outstanding

: 69.40% (As of Today)

View and export this data going back to 2015. Start your Free Trial

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ascendis Pharma A/S's float shares is 39.29 Mil. Ascendis Pharma A/S's total shares outstanding is 56.61 Mil. Ascendis Pharma A/S's float percentage of total shares outstanding is 69.40%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ascendis Pharma A/S's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ascendis Pharma A/S's Institutional Ownership is 84.56%.

Ascendis Pharma A/S Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Ascendis Pharma A/S's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	39.29	/	56.61
	=	69.40%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma A/S (Ascendis Pharma A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (NAS:ASND) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

ASND:Mexico A71:Germany A1SN34:Brazil

Address

Tuborg Boulevard 12, Hellerup, DNK, DK-2900

Website

http://www.ascendispharma.com

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.